Background: Panitumumab has the potential to improve the therapeutic ratio of concurrent chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN).
introduction
Approximately 560 000 people worldwide were diagnosed with squamous cell carcinoma of the head and neck (SCCHN) in 2008 [1] . Most present with locally advanced disease requiring multimodality therapy [2] . Multiple phase III trials have shown that platinum-based concurrent chemoradiotherapy (CRT) improves outcomes compared with radiotherapy alone [3] [4] [5] [6] [7] . Advances in surgical and radiation approaches to SCCHN have also occurred [2, 8, 9] . Despite this, survival is still <60% [1, 10] . For those who do survive, the long-term consequences of treatment impact significantly on quality of life (QoL) [11, 12] . Improving cure rates in SCCHN and minimizing the impact on QoL remain major challenges in the field.
Epidermal growth factor receptor (EGFR) is an attractive target in SCCHN on the basis of its widespread overexpression and association with poor prognosis [13] [14] [15] [16] . mAbs directed against EGFR have direct antitumor activity and are effective radiation sensitizers [17] . Earlier studies include a phase III trial investigating radiotherapy with or without the anti-EGFR mAb, cetuximab, in locally advanced SCCHN [18] . Locoregional control and survival were improved by the addition of cetuximab, while toxicity was not increased.
Recent data have also shown that anti-EGFR mAbs can improve outcomes in SCCHN when added to chemotherapy, as seen in the EXTREME study. This phase III clinical trial randomly assigned patients with recurrent and metastatic disease to receive standard chemotherapy plus or minus cetuximab and found that survival was significantly longer with cetuximab [19] .
Panitumumab is a fully human IgG2 mAb targeting EGFR. Panitumumab is potentially less immunogenic than chimeric mAbs, such as cetuximab, and rarely causes severe infusion reaction. Panitumumab also has a longer half-life and higher affinity for EGFR than other mAbs [20, 21] . Clinical trials have demonstrated single-agent activity in epithelial malignancies, including colorectal carcinoma [22, 23] . Moreover, preclinical studies indicate that panitumumab can improve SCCHN radiation sensitization by augmenting DNA damage and suppressing EGFR activation induced by radiation [24] .
We hypothesized that the addition of panitumumab to platinum-based CRT may improve antitumor activity without exacerbating toxicity. We therefore carried out this phase I study of concurrent panitumumab, carboplatin, paclitaxel and intensity-modulated radiotherapy (IMRT) for locally advanced SCCHN.
patients and methods

study design
This study was designed to investigate the safety, tolerability and recommended phase II dose of paclitaxel (Taxol, Bristol-Myers Squibb, New York City, NY) given concurrently with panitumumab, carboplatin and IMRT in SCCHN. The trial was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board. The primary end point was to determine the recommended phase II dose of paclitaxel in combination with fixed-dose panitumamab and carboplatin administered concurrently with once-daily radiotherapy. We investigated escalating doses of paclitaxel because, of the three drugs administered, paclitaxel is the most likely to exacerbate radiotherapy-related toxicity. A conventional 3 + 3 phase I design was used, followed by an expansion cohort of 10 patients to ensure that toxicity at the recommended phase II dose was acceptable. Secondary end points included the acute and long-term toxicity profiles, response rates, disease-free survival (DFS) and overall survival (OS).
The recommended phase II dose was defined as one dose level (DL) below that in which two or more dose-limiting toxic effects (DLTs) occurred in a maximum of six patients. Two DLs of paclitaxel were investigated, 15 and 30 mg/m 2 weekly. If the maximum DL was completed without two or more DLTs in six patients, this DL would be declared the recommended phase II dose. DLTs were graded throughout the treatment period according to the Common Terminology Criteria for Adverse Events v3.0 and defined as follows: (i) grade 3 or more non-hematologic toxicity considered to be a direct result of treatment, except untreated nausea, vomiting and diarrhea, dysphagia, esophagitis, mucositis/stomatitis attributed to CRT, dermatitis/ rash attributed to CRT and skin changes attributed to panitumumab (unless grade 3 or more skin rash or intolerable skin changes recurred despite measures taken for skin toxicity management); (ii) Grade 4 esophagitis or mucositis/stomatitis resulting in a radiotherapy break ‡7 days in aggregate; (iii) Grade 4 dermatitis resulting in a radiotherapy break ‡7 days in aggregate and (iv) grade 3 or more febrile neutropenia, ‡grade 4 neutropenia ‡7 days or grade 3 or more thrombocytopenia. Evaluation of response was carried out between weeks 8 and 10 following the last day of radiation and included PE, CT or MRI of the neck and PET/CT. Decision on neck dissection was made by the multidisciplinary team on a case-by-case basis, with neck dissection favored in any patient with N3 disease at presentation or evidence of persistent disease by clinical examination and/or radiographic imaging carried out in weeks 8-10. chemotherapy and panitumumab 
radiotherapy
Patients were treated using a dose-painting IMRT approach with a single plan to deliver 35 fractions once daily over 7 weeks. Primary and nodal gross disease was treated to 70 Gy. The high-and low-risk clinical target volumes received 64 and 60 Gy, respectively. Normal tissue constraints were set as part of the planning process. Appropriate tumor coverage was prioritized over normal tissue limits, unless in conflict with spinal cord dose.
statistical evaluation
All patients who received at least one fraction of radiation and/or dose of systemic therapy were evaluated for safety and response. Frequencies were used to report patient characteristics, toxicity and response rates. DFS was calculated from the date of registration to the earlier of disease recurrence or death from any cause. Patients alive without a recurrence were censored at the date of last contact. OS was calculated from the date of registration to the date of death from any cause, censored at the date of last contact. All patients received the prescribed radiation dose of 70 Gy to the gross tumor volume over a mean of 51 days (range 47-57 days). Three patients had brief radiation breaks: one in DL 1 for 3 days for grade 4 mucositis; one in DL 2 for 3 days for nausea and vomiting and one in DL 2 for 1 day for neck swelling. In all, systemic therapy was held in six patients (34%). One patient in DL 1 missed 1 week of all three drugs during the radiotherapy break detailed above. All other systemic therapy modifications occurred in DL 2. One patient had therapy held for nausea and vomiting, during a break from radiation as detailed above. The other four patients had systemic therapy, but not radiation, held for 1 week for grade 3 rash (n = 1), paclitaxel allergic reaction (n = 1) and grade 4 mucositis (n = 2). Table 3 shows acute toxic effects. Mucositis was the single most significant toxicity, with almost all events grade 3 or more. Nearly all patients experienced grade 1 or 2 oral pain and xerostomia and grade 3 dysphagia. Despite the placement of a PEG in all patients, 100% experienced grade 1 or 2 weight loss (median weight loss 11%). Dermatitis was observed in all patients, 11 of 19 (58%) grade 1 or 2 and 8 of 19 (42%) grade 3, but did not interfere with the administration of treatment. Eighteen patients (95%) experienced an acneiform rash. Rash was treated promptly and tended to clear rapidly once CRT was complete. Other frequent toxic effects included nausea, vomiting, diarrhea, weight loss and dehydration. The majority of these events were £grade 2. One patient in DL 1 developed a deep vein thrombosis. Paronychia occurred in two patients (10%). There were four mild paclitaxel infusion reactions. Six patients (31%) were treated for fever without neutropenia and one patient in DL 2 was treated for DLT-defining febrile neutropenia. One patient in DL 1 (33%) and 11 patients in DL 2 (69%) developed liver function test abnormalities, most of which were £grade 2 and resolved rapidly. Ten patients (53%) experienced £grade 2 hypomagnesemia and grade 2 or 3 hypokalemia occurred in five patients (26%).
Two patients in DL 2 developed serious complications several weeks after completing therapy. One patient experienced grade 4 sepsis, pulmonary emboli and stroke 3 weeks after the completion of therapy. The other patient developed grade 4 aspiration pneumonia and grade 3 empyema 11 weeks after completing therapy. Neither event was considered a DLT because they did not occur during therapy and were consistent with known complications from CRT to the head and neck. One patient was diagnosed with an unrelated prostate cancer 11 months after enrollment.
To date, most long-term salivary gland, mucosal and cutaneous toxic effects have been mild to moderate, £grade 2, except for one patient, who was diagnosed with radionecrosis of the tongue base 32 weeks after completing radiotherapy. All 19 patients had their PEG tubes removed at a median of 11 weeks (range 4-39 weeks), calculated from the completion of radiotherapy.
response to treatment
According to RECIST, 13 patients had evaluable primary tumors. Nine (69%) had complete responses and four (31%) had partial responses (PRs). All 19 patients had evaluable cervical adenopathy, and all 19 (100%) had PRs. TX  T1  T2  T3  T4  Total   N 0  -----0  N1  --6  --6  N2A  1  -1  --13  N2B  1  4  6  --0  N2C  -----0  N 3  -----0  Total  2  4  13  0  0  19 TNM, tumor-node-metastasis.
original article
Annals of Oncology Table 4 shows the overall clinical response per patient by CT or MRI, PET/CT, PE and neck dissection. The overall clinical response in the primary site was 100%. Two patients had suspicious neck adenopathy upon restaging. One patient presented with an HPV16-positive T2N2B base of tongue SCCHN. Restaging neck CT showed a PR in the neck. PET/CT was indeterminant and PE revealed a 2.5-cm palpable neck mass. Modified radical neck dissection was carried out, showing metastatic SCCHN in 1 of 60 lymph nodes. One other patient who presented with an HPV16-positive T2N2B tonsillar SCCHN underwent neck dissection. The patient's restaging neck CT showed a PR in the neck. PET/CT was indeterminant. PE indicated no residual disease. Modified radical neck dissection revealed one 4.5-cm lymph node with evidence of treatment effect, but no viable tumor cells were identified. Seventeen other nodes were negative.
One patient who presented with an HPV-negative T2N1 base of tongue SCCHN experienced a local recurrence at 12 months. There have been no other locoregional recurrences or distant metastases. All patients remained alive at a median follow-up of 21 months. discussion This is the first phase I clinical trial to investigate panitumumab plus CRT for treatment of locally advanced SCCHN. The recommended phase II dose is seven weekly infusions of panitumumab 2.5 mg/kg, carboplatin AUC of 1.5 and paclitaxel 
These events were not considered DLTs as they were not directly related to protocol treatment. DL, dose level; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLTs, dose-limiting toxic effects. This regimen was fairly well tolerated. Only one DLT occurred, a brief episode of febrile neutropenia. The acute toxic effects encountered were similar to those expected with CRT and include dysphagia, mucositis and radiation dermatitis. Nearly all patients developed grade 3 dysphagia, and most patients developed grade 3 or 4 mucositis but the majority of other toxic effects encountered were grade 1 or 2. Thus, incorporating panitumumab into CRT does not appear to exacerbate the acute toxic effects of therapy. Panitumumab introduced an additional side-effect of acneiform rash; however, this was easily managed.
Making a direct comparison to the side-effect profiles of other CRT regimens is difficult given differences in patient populations, regimens and toxicity reporting but can be helpful to gauge the tolerability of a new regimen. In our study, 84% of patients developed grade 3 or more mucositis and 42% developed grade 3 radiation dermatitis. The Intergroup 026 trial compared radiotherapy alone with two CRT schedules. Treatment on arm B was comprised of bolus cisplatin and once-daily radiotherapy. Forty-three percent of these patients developed grade 3 or more mucositis, and 7% of patients developed grade 3 or more radiation dermatitis. [5] Toxic effects encountered with cetuximab and radiotherapy can also be considered. Bonner et al. reported that grade 3 or more mucositis and dermatitis were encountered in 56% and 23% of patients, respectively [18] . While our rates of grade 3 or more mucositis and dermatitis were slightly higher, toxicity reporting is notoriously variable and toxicity rates are frequently underappreciated [26] . In fact, several more recent publications indicate that higher rates of radiation dermatitis and mucositis may be seen with cetuximab and radiotherapy for SCCHN. [27] [28] [29] [30] Giro et al. [29] report on findings from a survey sent to EORTC centers. Detailed data were available for 71 SCCHN patients treated with cetuximab and radiotherapy, 50% of whom developed grade 3 or more radiation dermatitis. Pryor et al. [30] report even higher rates of toxicity in a series of 13 consecutive SCCHN patients treated with cetuximab and radiotherapy, with 77% of patients experiencing grade 3 or more radiation dermatitis and 77% with grade 3 or more mucositis. Toxicity was clinically significant as it led to radiotherapy treatment breaks in 4 of the 13 patients. While neither study presents randomized controlled data, the data do indicate that acute radiation-related toxic effects may be exacerbated by anti-EGFR mAbs, after all. Compared with the Bonner study, these toxicity rates are more similar to the toxicity encountered in our study, implying that acute radiation-related toxicity with this panitumumab CRT regimen is perhaps not substantially worse than might be seen with concurrent radiotherapy plus anti-EGFR mAb therapy alone.
Markers of toxicity that are more objective than mucositis and dysphagia may serve as better end points for comparison between studies. Weight loss and PEG dependence rates are easily measured and are good surrogates for global toxicity [26] . In our study, weight loss was frequent but there was no grade 3 or more weight loss. Compared with cetuximab plus radiotherapy, with which 84% of patients experienced weight loss and 11% was grade 3 or more, the weight loss encountered in our study was relatively mild. Our PEG removal rate of 100% at a median of 11 weeks also compares favorably with other studies. In RTOG 0129, patients with stage III/IV SCCHN were entered in a randomized study of standard fractionated or concomitant boost radiotherapy, both with concurrent cisplatin [15] . One-year feeding tube dependence was 30% and 27%, respectively [31] . Similarly, 1-year feeding tube dependence was 18% with cetuximab plus radiotherapy [18] . While our study was comprised of a selected group of patients, our long-term toxicity results are encouraging given that most patients had oropharynx and hypopharynx primaries and indicate that panitumumab may offer a sparing effect on the normal oropharyngeal and upper esophageal tissues during CRT.
While response and survival were not the primary end points of this study, the results are worth noting. According to RECIST, all patients had a PR. This most likely substantially underrepresents the regimen's activity and highlights the limited utility of RECIST for determining response in SCCHN. Head and neck mucosal primary sites can be challenging to measure, and small residual cervical nodes on restaging scans are measurable according to RECIST but often do not represent residual disease. The summation of evaluations, including CT or MRI, PET and PE, may be a better representation of response. In this study, overall complete clinical response was 95%, and the one patient without a complete clinical response is alive and disease free after neck dissection. The 95% DFS and 100% OS at 21 months must be considered in the context that almost half the patients had good prognosis HPV16-associated oropharynx SCCHNs [32, 33] . Also, there were no patients with bulky T3/T4 primary tumors or N2c/ N3 disease. Lastly, the number of patients enrolled was small, and the period of follow-up is <3 years.
There is growing awareness that with current approaches to multimodality therapy, survival outcomes in SCCHN are indeed improving. As the number of survivors climbs, the burden of long-term toxicity is becoming an increasingly obvious problem. At this point, emphasis on improving cure rates must be coupled with efforts to mitigate toxicity as organ preservation without functional preservation is a pyrrhic victory. The addition of targeted therapies to CRT may be an ideal approach to improve the therapeutic ratio in SCCHN. Treatment can be intensified by the addition of the targeted agent, while further intensification of chemotherapy and radiation is avoided. If the added toxic effects are modest and do not exacerbate the side-effect profile of CRT, all aspects of the therapeutic ratio are enhanced. As we show in this phase I study, panitumumab can be safely added to concurrent carboplatin, paclitaxel and IMRT to create a well-tolerated regimen that appears highly active in the curative treatment of SCCHN. Further study of this regimen in head and neck cancer is warranted, though should be done with caution, and in an appropriate high-risk population, as the addition of targeted therapies to CRT may increase acute and chronic toxic effects that would not be justifiable in the absence of improved rates of cure and survival. 
